Showing 2021-2030 of 2038 results for "".
- Allergan Launches New Refresh Repair Lubricant Eye Dropshttps://modernod.com/news/allergan-launches-new-refresh-repair-lubricant-eye-drops/2480034/Allergan announced the launch of a new over-the-counter artificial tear formulation, Refresh Repair Lubricant Eye Drops. The first and only artificial tear in the U.S. formulated with carboxymethylcellulose (CMC), hyaluronic acid (HA, an inactive ingredient), and osmoprotectants, Refresh Repair
- EyeSouth Partners Develops of Physician Advisory Boardhttps://modernod.com/news/eyesouth-partners-develops-of-physician-advisory-board/2480041/As part of its continuing focus on the highest quality patient outcomes, EyeSouth Partners, a network of integrated eye care practices located throughout the Southeast, announced the formation of its physician advisory board. Its responsibilities will include overseeing clinical policies and proc
- Market Scope: New Products Poised to Drive Glaucoma Pharma Market to $6.6 Billion by 2023https://modernod.com/news/market-scope-new-products-poised-to-drive-glaucoma-pharma-market-to-6-6-billion-by-2023/2480067/The launches of Vyzulta, Rhopressa, and preservative-free formulations promise to boost manufacturers’ revenues during the next 5 years in the global glaucoma pharmaceuticals market. The upswing follows years of declining revenues as branded products lost patent protection and the market s
- Bausch + Lomb Launches Soothe Xtra Protection Preservative Free Lubricant Eye Dropshttps://modernod.com/news/bausch-lomb-launches-soothe-xtra-protection-preservative-free-lubricant-eye-drops/2480089/Bausch + Lomb announced the introduction of Soothe Xtra Protection (XP) Preservative Free lubricant eye drops. “Soothe XP Preservative Free provides a new eye drop option for the increasing number of people suffering from dry eye symptoms who are looking for a preservative-free formu
- Wize Pharma Announces Presentation of New Data on LO2A in the Treatment of Dry Eye Syndrome in Patients with Sjögren’s Syndromehttps://modernod.com/news/wize-pharma-announces-presentation-of-new-data-on-lo2a-in-the-treatment-of-dry-eye-syndrome-in-patients-with-sjogrens-syndrome/2480143/Wize Pharma announced recently reported new data on a formula known as LO2A, a product that Wize has in-licensed certain rights to purchase, market, sell and distribute. The poster presentation presented at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting
- Ex-Valeant Executive Guilty of Taking Pharmacy CEO’s Bribehttps://modernod.com/news/ex-valeant-executive-guilty-of-taking-pharmacy-ceos-bribe/2480147/A former Valeant Pharmaceuticals executive was found guilty of accepting a $10 million bribe for manipulating the company’s takeover of a startup mail-order pharmacy in 2014, according to a
- Valeant Will Become Bausch Health Companieshttps://modernod.com/news/valeant-will-become-bausch-health-companies-inc/2480165/Valeant Pharmaceuticals International announced that the company will change its name to Bausch Health Companies beginning in July 2018. “Becoming Bausch Health Companies is a major step forward in our transformation,” Joseph C. Papa, chairman and CEO, Valeant, said in a compan
- US Sales of Eylea in First Quarter Best Estimateshttps://modernod.com/news/us-sales-of-eylea-in-first-quarter-best-estimates/2480174/Regeneron Pharmaceuticals reported Thursday that first-quarter sales of Eylea in the US rose 15 percent year-over-year to $984 million, besting analyst estimates of around $922 million. The company’s overall sales increased 15 percent to $1.5 billion, in line with forecasts, as net income s
- Ocugen Presents Preclinical Efficacy Data of its Proprietary Nanoemulsion Technology at ARVO 2018https://modernod.com/news/ocugen-presents-preclinical-efficacy-data-of-its-proprietary-nanoemulsion-technology-at-arvo-2018/2480184/Ocugen announced that it presented additional preclinical findings in a poster highlighting the potential efficacy of its unique, patented nanoemulsion formulation of brimonidine tartrate (OCU300) at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting, held
- Market Scope: China’s Ophthalmic Market to grow 11.3% to $4.5 Billion in 2023https://modernod.com/news/market-scope-chinas-ophthalmic-market-to-grow-11-3-to-4-5-billion-in-2023/2480211/Market Scope forecasts that China’s $2.6 billion ophthalmic market will grow at a compound annual rate of 11.3 percent over the next 5 years to $4.5 billion in 2023. China has tremendous unmet need for ophthalmic care. The country is home to approximately one-third of the world’s blind peo